

April 16, 2015



Molecular Templates Presents Preclinical Data on De-Immunized Engineered Toxin Bodies (ETB) with Novel Immuno-Oncology Capabilities at the 2015 AACR Annual Meeting

- Presentation includes report on the development of CD38- and HER2-targeting lead drug candidates that incorporate the Company's proprietary de-immunization and novel immuno-oncology technologies

GEORGETOWN, Texas--(BUSINESS WIRE)-- Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of next generation immunotoxin therapies called Engineered Toxin Bodies (ETBs) announced today that it will present preclinical data in a poster presentation at the 2015 American Association for Cancer Research (AACR) Meeting in Philadelphia, PA on Monday, April 20th, 2015. In the presentation, entitled "Engineered Toxin Bodies: A next-generation immunotoxin scaffold with novel immuno-oncology functionality" (Abstract 2477), the company reports on the development of proprietarily de-immunized ETBs that can kill tumor cells through an enzymatic shut-down of protein synthesis but can also simultaneously "seed" tumor cells with foreign class I antigens on the target cell surface that can be recognized by high avidity native T-cells. The company is advancing two leads using this technology that target CD38 and HER2.

"We are excited to present preclinical data that demonstrate the continued innovation around our platform technology and these two maturing lead programs," said Eric Poma, CEO and CSO, Molecular Templates. "Our technology represents a new class of targeted therapies with distinct advantages over traditional ADC therapies and now a potential alternative approach to immuno-oncology distinct from checkpoint inhibition or CAR-T approaches. Our lead compound, MT-3724, has entered clinical studies this year for lymphoma and our CD38 and HER2 programs are advancing toward the clinic as well."

About Molecular Templates

Molecular Templates is a biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs). Engineered Toxin Bodies are targeted biologic therapies that incorporate the Company's next-generation de-immunization technology and Antigen Seeding Technology (AST). The company is pursuing development of various leads across a wide range of cancers.

Molecular Templates, Inc.

Jason Kim, 512-639-0206
President & CFO
Fax: 512-233-2709
jason.kim@moleculartemplates.com
www.moleculartemplates.com

Source: Molecular Templates, Inc.